The cloud computing company’s cofounder Brannin McBee spoke to Forbes about the “important milestone” as shares started ...
VESPER-2 is a 28-week Phase 2b clinical trial assessing the efficacy and tolerability of different weekly doses of MET-097i with or without titration. The trial enrolled the first participant in March ...